United Therapeutics Soars As Study Results Bring 'New Era'
United Therapeutics stock soared on Phase 3 study results showing Tyvaso reduced risk for idiopathic pulmonary fibrosis patients.

Source: Investor's Business Daily
United Therapeutics stock soared on Phase 3 study results showing Tyvaso reduced risk for idiopathic pulmonary fibrosis patients.